SCHEMBL5396309

SCHEMBL5396309

O=S(=O)(Nc1nnc(C(F)(F)F)s1)c1ccc(F)cc1

nearest known ligand 0.77

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.77
MEN1 O00255 6/20 0.77
ALDH1A1 P00352 8/20 0.60
HPGD P15428 2/20 0.60
HSD17B10 Q99714 2/20 0.60
HTT P42858 3/20 0.57
LMNA P02545 2/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
TP53 P04637 1/20 0.57
CA1 P00915 2/20 0.56
CA2 P00918 2/20 0.56
CA4 P22748 1/20 0.56
CA5A P35218 1/20 0.56
CA5B Q9Y2D0 1/20 0.56
MAPT P10636 2/20 0.54
TSHR P16473 1/20 0.54
PKM P14618 2/20 0.51
AKT1 P31749 1/20 0.48
GAA P10253 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5391647 0.87 MEN1 (0.75) KMT2AMEN1ALDH1A1HPGDHSD17B10
SCHEMBL5391636 0.87 MEN1 (1.00) KMT2AMEN1ALDH1A1HPGDHSD17B10
SCHEMBL5397691 0.87 MEN1 (0.75) KMT2AMEN1ALDH1A1HPGDHSD17B10
SCHEMBL5394860 0.87 MEN1 (0.74) KMT2AMEN1ALDH1A1HPGDHSD17B10
SCHEMBL5389518 0.81 MEN1 (0.74) KMT2AMEN1ALDH1A1HPGDHSD17B10
Hydrochloric Acid SCHEMBL3789519 0.80 MEN1 (0.65) KMT2AMEN1ALDH1A1HPGDHSD17B10
SCHEMBL5385416 0.78 KMT2A (0.62) KMT2AMEN1LMNACA1CA2
SCHEMBL5401314 0.75 ALDH1A1 (0.71) KMT2AALDH1A1HPGDHSD17B10HTT
SCHEMBL5389533 0.75 ALDH1A1 (1.00) KMT2AMEN1ALDH1A1HPGDHSD17B10
SCHEMBL27183365 0.74 CA1 (0.67) KMT2AMEN1ALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7173030-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2007-02-06 US claimed
EP-1631558-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I BIOVITRUM AB (SE) 2006-03-08 EP claimed
US-20050009821-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB 2005-01-13 US claimed
WO-2004103980-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I BIOVITRUM AB (SE) 2004-12-02 WO claimed
US-20070066614-A1 Ihibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB 2007-03-22 US disclosed
US-7173030-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2007-02-06 US disclosed
EP-1631558-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I BIOVITRUM AB (SE) 2006-03-08 EP disclosed
US-20050009821-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB 2005-01-13 US disclosed
WO-2004103980-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I BIOVITRUM AB (SE) 2004-12-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009821-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD11B2 KMT2A 3325/4885MEN1 942/4885ALDH1A1 53/4885
US-20070066614-A1 Ihibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD17B11 KMT2A 3281/4885MEN1 974/4885ALDH1A1 36/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.